Form D · Pharmaceuticals
Chase Therapeutics Corp
Washington, DC · CIK 0001723805
Offering snapshot reported Aug 28, 2018 · SEC filing
- Reported sold
- $4M Offering amount: $4M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Aug 21, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 28, 2018 | Initial | $4,000,000 | No comparison | 3 | SEC filing |
| Nov 29, 2017 | Initial | $1,300,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-320230
This filing covers the sale and issuance of Series A-2 Preferred Stock and the underlying Common Stock issuable upon conversion thereof.
Source: Form D, filed Aug 28, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas N. Chase | Director, Executive |
| Kathleen Clarence Smith | Director |
| Richard P. Dulik | Executive |
| Karoly Nikolich | Director |
| John Reher | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1825 K Street Nw Suite 510
Washington, DC, 20006
Washington, DC, 20006